Search Results - "Scher, H"

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study by Slovin, S.F., Higano, C.S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J.J., Scher, H.I., Chin, K., Gagnier, P., McHenry, M.B., Beer, T.M.

“…This phase I/II study in patients with metastatic castration-resistant prostate cancer (mCRPC) explored ipilimumab as monotherapy and in combination with…”
Get full text

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 by Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., Tombal, B.

“…The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most…”
Get full text

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial by Sternberg, C.N., de Bono, J.S., Chi, K.N., Fizazi, K., Mulders, P., Cerbone, L., Hirmand, M., Forer, D., Scher, H.I.

“…The randomized, double-blind phase III AFFIRM trial demonstrated that enzalutamide, an oral androgen receptor inhibitor, significantly prolonged overall…”
Get full text

Expanded oxygen minimum zones during the late Paleocene‐early Eocene: Hints from multiproxy comparison and ocean modeling by Zhou, X., Thomas, E., Winguth, A. M. E., Ridgwell, A., Scher, H., Hoogakker, B. A. A., Rickaby, R. E. M., Lu, Z.

“…Anthropogenic warming could well drive depletion of oceanic oxygen in the future. Important insight into the relationship between deoxygenation and warming can…”
Get full text

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts by Lorente, D., Olmos, D., Mateo, J., Dolling, D., Bianchini, D., Seed, G., Flohr, P., Crespo, M., Figueiredo, I., Miranda, S., Scher, H.I., Terstappen, L.W.M.M., de Bono, J.S.

“…The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating…”
Get full text

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel by Chi, K.N., Kheoh, T., Ryan, C.J., Molina, A., Bellmunt, J., Vogelzang, N.J., Rathkopf, D.E., Fizazi, K., Kantoff, P.W., Li, J., Azad, A.A., Eigl, B.J., Heng, D.Y.C., Joshua, A.M., de Bono, J.S., Scher, H.I.

“…Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently…”
Get full text

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer by Scher, H.I., Armstrong, A.J., Schonhoft, J.D., Gill, A., Zhao, J.L., Barnett, E., Carbone, E., Lu, J., Antonarakis, E.S., Luo, J., Tagawa, S., dos Anjos, C.H., Yang, Q., George, D., Szmulewitz, R., Danila, D.C., Wenstrup, R., Gonen, M., Halabi, S.

“…To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic…”
Get full text

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer by Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C

“…Background: Prostate cancer remains dependent of androgen receptor (AR) signalling, even after emergence of castration resistance. EZN-4176 is a…”
Get full text

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy by Sternberg, C.N., Molina, A., North, S., Mainwaring, P., Fizazi, K., Hao, Y., Rothman, M., Gagnon, D.D., Kheoh, T., Haqq, C.M., Cleeland, C., de Bono, J.S., Scher, H.I.

“…Fatigue is a common, debilitating side-effect of prostate cancer and its treatment. Patient-reported fatigue was evaluated as part of COU-AA-301, a randomized,…”
Get full text

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide by Rathkopf, D.E., Smith, M.R., Ryan, C.J., Berry, W.R., Shore, N.D., Liu, G., Higano, C.S., Alumkal, J.J., Hauke, R., Tutrone, R.F., Saleh, M., Chow Maneval, E., Thomas, S., Ricci, D.S., Yu, M.K., de Boer, C.J., Trinh, A., Kheoh, T., Bandekar, R., Scher, H.I., Antonarakis, E.S.

“…Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation…”
Get full text

Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) by Scher, H.I., Graf, R.P., Hulling, M., Carbone, E., Dittamore, R.

Get full text

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer by Goodman, O B, Flaig, T W, Molina, A, Mulders, P F A, Fizazi, K, Suttmann, H, Li, J, Kheoh, T, de Bono, J S, Scher, H I

“…Background: Visceral disease, non-nodal soft-tissue metastases predominantly involving the lung and liver, is a negative prognostic factor in patients with…”
Get full text

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium by Grossman, RL, Abel, B, Angiuoli, S, Barrett, JC, Bassett, D, Bramlett, K, Blumenthal, GM, Carlsson, A, Cortese, R, DiGiovanna, J, Davis‐Dusenbery, B, Dittamore, R, Eberhard, DA, Febbo, P, Fitzsimons, M, Flamig, Z, Godsey, J, Goswami, J, Gruen, A, Ortuño, F, Han, J, Hayes, D, Hicks, J, Holloway, D, Hovelson, D, Johnson, J, Juhl, H, Kalamegham, R, Kamal, R, Kang, Q, Kelloff, GJ, Klozenbuecher, M, Kolatkar, A, Kuhn, P, Langone, K, Leary, R, Loverso, P, Manmathan, H, Martin, A‐M, Martini, J, Miller, D, Mitchell, M, Morgan, T, Mulpuri, R, Nguyen, T, Otto, G, Pathak, A, Peters, E, Philip, R, Posadas, E, Reese, D, Reese, MG, Robinson, D, Dei Rossi, A, Sakul, H, Schageman, J, Singh, S, Scher, HI, Schmitt, K, Silvestro, A, Simmons, J, Simmons, T, Sislow, J, Talasaz, A, Tang, P, Tewari, M, Tomlins, S, Toukhy, H, Tseng, HR, Tuck, M, Tzou, A, Vinson, J, Wang, Y, Wells, W, Welsh, A, Wilbanks, J, Wolf, J, Young, L, Lee, JSH, Leiman, LC

“…The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic,…”
Get full text

Enzalutamide: Development from bench to bedside by Bambury, R.M, Scher, H.I

“…Abstract Prostate tissue, whether benign or malignant, is heavily dependent on androgen receptor (AR) signaling for growth and proliferation. Androgen…”
Get full text

ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression by PEDUTO, L, REUTER, V. E, SEHARA-FUJISAWA, A, SHAFFER, D. R, SCHER, H. I, BLOBEL, C. P

“…The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for…”
Get full text

Periprostatic adipose inflammation is associated with high-grade prostate cancer by Gucalp, A, Iyengar, N M, Zhou, X K, Giri, D D, Falcone, D J, Wang, H, Williams, S, Krasne, M D, Yaghnam, I, Kunzel, B, Morris, P G, Jones, L W, Pollak, M, Laudone, V P, Hudis, C A, Scher, H I, Scardino, P T, Eastham, J A, Dannenberg, A J

“…Background: Obesity, a cause of subclinical inflammation, is associated with increased risk of high-grade prostate cancer (PC) and poor outcomes. Whether…”
Get full text

Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase by SIROTNAK, Francis M, ZAKOWSKI, Maureen F, MILLER, Vincent A, SCHER, Howard I, KRIS, Mark G

“…The blockade of epidermal growth factor receptor (EGFR) function with monoclonal antibodies has major antiproliferative effects against human tumors in vivo …”
Get full text

Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials by Fizazi, K., Flaig, T.W., Stöckle, M., Scher, H.I., de Bono, J.S., Rathkopf, D.E., Ryan, C.J., Kheoh, T., Li, J., Todd, M.B., Griffin, T.W., Molina, A., Ohlmann, C.H.

“…The usefulness of Gleason score (<8 or ≥8) at initial diagnosis as a predictive marker of response to abiraterone acetate (AA) plus prednisone in patients with…”
Get full text

Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems by Hornberger, J., Graf, R.P., Hulling, M., Attard, G., Allan, A., Dittamore, R., Scher, H.I.

Get full text

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations by Abida, W., Bryce, A.H., Vogelzang, N.J., Amato, R.J., Percent, I., Shapiro, J.D., McDermott, R., Hussain, A., Patnaik, A., Petrylak, D., Ryan, C.J., Stanton, T., Zhang, J., Simmons, A.D., Despain, D., Collins, M., Golsorskhi, T., Scher, H.I., Chowdhury, S.

Get full text